76.92

3.26% -2.59

Pre-market: 78.75 1.83 +2.38%

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $76.92, with a volume of 2.22M. It is down -3.26% in the last 24 hours and up +6.21% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$79.51

Open:

$79.31

24h Volume:

2.22M

Relative Volume:

1.00

Market Cap:

$9.05B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

25.47

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

-1.91%

1M Performance:

+6.21%

6M Performance:

+20.11%

1Y Performance:

+32.37%

1-Day Range:

$76.10

$79.53

1-Week Range:

$76.10

$82.22

52-Week Range:

$47.50

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

350

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	76.92	9.35B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

Feb 11, 2026

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve

Feb 11, 2026

Feb 10, 2026

Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz

Feb 10, 2026

Biotech: Halozyme CEO explains what it looks for in M&A targets - Yahoo Finance

Feb 10, 2026

Profund Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Feb 10, 2026

Halozyme Therapeutics (HALO) to Release Earnings on Tuesday - MarketBeat

Feb 10, 2026

Feb 09, 2026

Halozyme Expecting Decade of Growth - San Diego Business Journal

Feb 09, 2026

Feb 07, 2026

New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Feb 07, 2026

Renaissance Group LLC Invests $35.11 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Feb 07, 2026

Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Sahm

Feb 07, 2026

Feb 06, 2026

Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com - Investing.com Nigeria

Feb 06, 2026

Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month HighTime to Buy? - MarketBeat

Feb 06, 2026

Halozyme Therapeutics stock hits all-time high at 79.99 USD - Investing.com

Feb 06, 2026

A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Yahoo Finance

Feb 06, 2026